Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
March 9, 2022 4:00 PM EST- Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million
- Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022
- Conference call to provide business updates today, March 9 at 1:30 p.m. PT/4:30 p.m. ET
... More
